Selective Inhibition of Cyclooxygenase-2 Suppresses the Growth of Pancreatic Cancer Cells in Vitro and in Vivo
Open Access
- 1 January 2008
- journal article
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 215 (2) , 149-157
Abstract
Cyclooxygenase-2 (COX-2), a prostaglandin synthetase, is involved in development of certain tumors. We therefore analyzed COX-2 expression in pancreatic cancer tissues (53 samples) and Panc-1 human pancreatic cancer cells by immunohistochemistry, RT-PCR and western-blotting analyses. Also, immunohistochemistry of proliferating cell nuclear antigen (PCNA) was performed. We found expression of COX-2 was dramatically upregulated in 36 of 53 cases (67.9%) and the expression of COX-2 was associated with the diameter (> 3 cm) of the tumors (p < 0.05), but not with the age, gender, tumor location, differentiation, lymph-node metastases and TNM stage. The positivity rate of PCNA expression in the pancreatic cancer cells of the COX-2 positive group (32.88 ± 13.26%) was significantly higher than that in the COX-2 negative group (24.56 ± 11.51%) (p < 0.05). Then we investigated the effect of selective inhibitors of COX-2 (NS398 and celecoxib) on proliferation of Panc-1 cells by 3-(4,5 dimethyl-2-thiazolyl)-2.5-diphenyl-2H-tetrazolium bromide (MTT) assay. Either NS398 or celecoxib suppressed proliferation of Panc-1 cells dose-dependently in vitro. Furthermore, Panc-1 cells were implanted into nude mice, and celecoxib was administrated orally with feed. The volume of the tumor xenografted into nude mice was decreased by 51.6% in the celecoxib group (p < 0.01). In conclusion, the increased expression of COX-2 may be responsible for rapid proliferation of pancreatic cancer, and specific inhibition of COX-2 suppresses proliferation of Panc-1 cells in vitro and in nude mice. The selective inhibitor of COX-2 may be an effectual agent for pancreatic cancer chemoprevention.Keywords
This publication has 20 references indexed in Scilit:
- Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric CancerJournal of Clinical Oncology, 2007
- Targeting Cyclooxygenase-2 and the Epidermal Growth Factor Receptor for the Prevention and Treatment of Intestinal CancerCancer Research, 2007
- Inhibition of COX‐2 with NS‐398 decreases colon cancer cell motility through blocking epidermal growth factor receptor transactivation: possibilities for combination therapyCell Proliferation, 2007
- CelecoxibDrugs, 2007
- Pancreatic cancer: a review of recent advancesExpert Opinion on Investigational Drugs, 2006
- RETRACTED: Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2Cancer Research, 2004
- Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent InvasionJournal of Biological Chemistry, 2002
- The MEK/ERK pathway mediates COX‐2‐selective NSAID‐induced apoptosis and induced COX‐2 protein expression in colorectal carcinoma cellsInternational Journal of Cancer, 2002
- Expression of cyclooxygenase 1 and 2 by human gastric endothelial cellsGut, 1999
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell, 1988